Effect of Adding Electroacupuncture to Anti-cancer Therapy-induced Peripheral Neuropathy
Condition(s) studied
Investigational drug(s) / intervention(s)
True acupuncture + standard anti chemotherapy-induced peripheral neuropathy treatment: Participants will receive a total of 8 treatments over 6 weeks, with twice a week treatments for the first and the forth weeks and weekly treatment for the remaining weeks.The acupuncturists will insert needles into the acupoints and manipulate the needles until"de qi"sensation is achieved and reported by the participants. In the meantime, participants will receive the same standard anti-CIPN treatments.
Sham acupuncture +standard anti chemotherapy-induced peripheral neuropathy treatment: The sham acupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group. Care was taken to avoid "de qi" sensation. In the meantime, participants will receive the same standard anti-CIPN treatments.
Study summary
This study is being done to evaluate the potential benefits of using electroacupuncture to reduce the severity of chemotherapy-induced peripheral neuropathy for patients with peripheral neuropathy after chemotherapy.
Eligibility
Primary outcome measure(s)
- Difference of the CIPN grade from baseline to week 6 after baseline — From enrollment to week 6
The primary outcome will be the proportion of patients whose CIPN grade improved after the completion of 8 acupuncture treatments sessions.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Zhongnan hospital of Wuhan University | Wuhan | Hubei | Recruiting |
More Zhongnan Hospital trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06858709 on ClinicalTrials.gov ↗ ← All trials in China